Entrada Therapeutics

Forecast & Rating9 analysts currently cover Entrada Therapeutics, with about 77.8% giving a positive rating — meaning they expect the stock to rise. The average price target is $18.75, about 221.6% upside from the current price of $5.83. Price targets range from $10.00 to $25.00 — a wide spread, showing clear disagreement over just how much Entrada Therapeutics can rise. Historically, about 48.1% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Entrada Therapeutics closely still see room for the stock to rise. Data as of Jul 20, 2026; for reference only and not investment advice.